DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs

Information source: Hospices Civils de Lyon
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Indapamide (Drug); Perindopril (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Hospices Civils de Lyon

Official(s) and/or principal investigator(s):
Francois GUEYFFIER, MD, Principal Investigator, Affiliation: Hospices Civils de Lyon

Overall contact:
François GUEYFFIER, MD, Phone: 33 472 119 057, Email: francois.gueyffier@chu-lyon.fr

Summary

The principal scientific objective of the trial is to identify the factors that are associated with differential blood pressure responses between drugs. This may allow investigators to produce new hypotheses on the pathophysiology of hypertension and on the mechanisms of drug action.

These factors can be of different types:

- Environmental factors (sodium or alcohol intake);

- Morphological (height, weight, body mass index, body surface area);

- Initial blood pressure;

- Electrocardiogram (ECG) parameters of left ventricular hypertrophy;

- Biological parameters as the activity level of the renin angiotensin aldosterone

system;

- Genetic polymorphisms.

Clinical Details

Official title: IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study

Primary outcome: Blood pressure at the end of each 4 week treatment period

Eligibility

Minimum age: 25 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participants have to be 25 to 60 years of age

- Both genders

- Systolic blood pressure of 140 mmHg or above; diastolic blood pressure of 90 mmHg or

above.

- Cardiovascular risk must not be high, to allow for two periods of 4 weeks of placebo

without ethical concern.

Locations and Contacts

François GUEYFFIER, MD, Phone: 33 472 119 057, Email: francois.gueyffier@chu-lyon.fr

Hôpital Louis Pradel, BRon 69677, France; Recruiting
François GUEYFFIER, MD, Phone: 33 472 119, Ext: 057, Email: francois.gueyffier@chu-lyon.fr
François GUEYFFIER, MD, Principal Investigator
Additional Information

Starting date: October 2004
Last updated: October 3, 2007

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008